Low-grade inflammation, and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk

Metabolism: Clinical and Experimental

Volumn 60, Issue 4, 2011, Pages 499-512

  Onat, Altan ^a,b   Hergenç, Gülay ^c  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c YILDIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C3; C REACTIVE PROTEIN; FIBRIC ACID DERIVATIVE; FISH OIL; GLUCOSE; HAPTOGLOBIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; SEX HORMONE BINDING GLOBULIN;

ARTICLE; CARDIOMETABOLIC RISK; CIGARETTE SMOKING; CORONARY RISK; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; ETHNIC DIFFERENCE; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HIGH DENSITY LIPOPROTEIN DYSFUNCTION; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK; RISK ASSESSMENT; SEX DIFFERENCE; TURKEY (REPUBLIC);

EID: 79952984934     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.04.018     Document Type: Review

References (97)

1. Mackness M.I., Arrol S., and Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein FEBS Lett 286 1991 152 154
2. Garner B., Waldeck A.R., Witting P.K., Rye K.A., and Stocker R. Oxidation of high-density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII J Biol Chem 273 1998 6088 6095 (Pubitemid 28144688)
3. Cockerill G.W., Rye K.A., Gamble J.R., Vadas M.A., and Barter P.J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules Arterioscler Thromb Vasc Biol 15 1995 1987 1995
4. Sorrentino S.A., Besler C., Rohrer L., Meyer M., Heinrich K., and Bahlmann F.H. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy Circulation 121 2010 110 122
5. Wadham C., Albanese N., Roberts J., Wang L., Bagley C.J., and Gamble J.R. High-density lipoproteins neutralize C-reactive protein proinflammatory activity Circulation 109 2004 2116 2122 (Pubitemid 38620221)
6. Epand R.M., Stafford A., Leon B., Lock P.E., Tytler E.M., and Segrest J.P. HDL and apolipoproteins A-I protect erythrocytes against the generation of procoagulant activity Arterioscler Thromb 14 1994 1775 1783
7. Nofer J.R., Levkau B., Wolinska I., Junker R., Fobker M., and von Eckardstein A. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids J Biol Chem 276 2001 34480 34485
8. Calvo C., Ponsin G., and Berthezene F. Characterization of the nonenzymatic glycation of high density lipoprotein in diabetic patients Diabetes Metab 14 1988 264 269
9. Ansell B.J., Navab M., Hama S., Kamranpour N., Fonarow G., and Hough G. Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment Circulation 108 2003 2751 2756 (Pubitemid 37498976)
10. Castellani L.W., Navab M., Van Lenten B.J., Hedrisk C.C., Hama S.Y., and Gotto A.M. Overexpression of apolipoprotein AII in transgenic mice converts high density lipoprotein to proinflammatory particles J Clin Invest 100 1997 464 474 (Pubitemid 27349095)
11. van Acker B.A.C., Botma G.J., Zwinderman A.H., Koivenhoven J.A., Dallinge-Thie G.M., and Sijbrands E.J.G. REGRESS Study Group. High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesterol ester transfer protein and hepatic lipase gene variants Atherosclerosis 200 2008 161 167
12. van der Steeg W.A., Holme I., Boekholdt S.M., Larsen M.L., Lindahl C., and Stroes E.S. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies J Am Coll Cardiol 51 2008 634 642 (Pubitemid 351186873)
13. Onat A., Can G., Ayhan E., Kaya Z., and Hergenç G. Impaired protection against diabetes and coronary disease by high-density lipoproteins in Turks Metabolism 58 2009 1393 1399
14. Onat A., Hergenç G., Bulur S., Uǧur M., Küçükdurmaz Z., and Can G. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks Int J Cardiol 2009 10.1016/j.ijcard.2008.12.066 [Epub]
15. Onat A., Hergenç G., Ayhan E., Uǧur M., and Can G. Impaired anti-inflammatory function of apolipoprotein A-II concentrations predict metabolic syndrome and diabetes at 4 years follow-up in elderly Turks Clin Chem Lab Med 47 2009 1389 1394
16. Onat A., Hergenç G., Dursunoǧlu D., Küçü kdurmaz Z., Bulur S., and Can G. Relatively high levels of serum adiponectin in obese women, a potential indicator of anti-inflammatory dysfunction: relation to sex hormone-binding globulin Int J Biol Sci 4 2008 208 214
17. Onat A., AvcI G.Ş., Şenocak M., Örnek E., and Gözükara Y. Plasma lipids and their interrelation in Turkish adults J Epidem Commun Health 46 1992 470 476
18. Onat A. Risk factors and cardiovascular disease in Turkey Atherosclerosis 156 2001 1 10 (Pubitemid 32429589)
19. Onat A., Ceyhan K., Başar Ö., Erer B., Toprak S., and Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels-a prospective and cross-sectional evaluation Atherosclerosis 165 2002 285 289
20. Mahley R.W., Palaoǧlu K.E., Atak Z., Dawson-Pepin J., Langlois A.M., and Cheung V. Turkish Heart Study: lipids, lipoproteins, and apolipoproteins J Lipid Res 36 1995 839 859
21. Onat A., Dursunoǧlu D., and Sansoy V. Relatively high coronary death and event rates in Turkish women: relation to three major risk factors in five-year follow-up of cohort Int J Cardiol 61 1997 69 78
22. Uysal K.T., Wiesbrock S.M., Marino M.W., and Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function Nature 389 1997 610 614 (Pubitemid 27446179)
23. Venugopal S.K., Devaraj S., Yuhanna I., Shaul P., and Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells Circulation 106 2002 1439 1441
24. Pasceri V., Willerson J.T., and Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells Circulation 102 2000 2165 2168
25. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., and Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus JAMA 286 2001 327 334 (Pubitemid 32656163)
26. Liu S., Tinker L., Song Y., Rifai N., Bonds D.E., and Cook N.R. A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women Arch Intern Med 167 2007 1676 1685 (Pubitemid 47280350)
27. Donath M.Y., Schumann D.M., Faulenbach M., Ellingsgaard H., Perren A., and Ehses J.A. Islet inflammation in type 2 diabetes: from metabolic stress to therapy Diabetes Care 31 Suppl 2 2008 S161 S164
28. Wu T., Dorn J.P., Donahue R.P., Sempos C.T., and Trevisan M. Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin. The Third National Health and Nutrition Examination Survey, 1988-1994 Am J Epidemiol 155 2002 65 71 (Pubitemid 34042434)
29. Hotamisligil G.S. Inflammation and metabolic disorders Nature 444 2006 860 867 (Pubitemid 46024993)
30. Brunner E.J., Kiwimäki M., Witte D.R., Lawlor D.A., Davey Smith G., and Cooper J.A. Inflammation, insulin resistance, and diabetes-mendelian randomization using CRP haplotypes points upstream PLoS Med 5 2008 e155.1278 e155.1285
31. Onat A., Can G., and Hergenç G. Serum C-reactive protein is an independent risk factor predicting cardiometabolic risk Metabolism 57 2008 207 214
32. Rifai N., and Warnick G.R. Lipids, lipoproteins, apolipoproteins, and other cardiovascular risk factors C.A. Burtis, E.R. Ashwood, D.E. Bruns, Tietz textbook of clinical chemistry and molecular diagnostics. 4th Ed. 2006 Elsevier Saunders St. Louis (Mo) 903 981
33. The Emerging Risk Factors Collaboration C-reactive protein concentration and the risk of coronary heart disease, stroke and mortality: an individual participant meta-analysis Lancet 375 2010 132 140
34. Steinberg D., and Witztum J.L. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 105 2002 2107 2111 (Pubitemid 34465275)
35. Libby P. Fat fuels the flame: triglyceride-rich lipoproteins and arterial inflammation Circ Res 100 2007 299 301
36. Ting H.J., Stice J.P., Schaff U.Y., Hui D.Y., Rutledge J.C., and Knowlton A.A. Triglyceride-rich lipoproteins prime aortic endothelium for inflammatory responses to TNF-α Circ Res 100 2007 381 390
37. Kawakami A., and Yoshida M. Apolipoprotein CIII links dyslipidemia with atherosclerosis J Atheroscler Thromb 16 2009 6 11
38. de Jager J., Dekker J.M., Kooy A., Kostense P.J., Nijpels G., and Heine R.J. Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: the Hoorn Study Arterioscler Thromb Vasc Biol 26 2006 1086 1093 (Pubitemid 43732116)
39. Qiao Q., Pyörälä K., Pyörälä M., Nissinen A., Lindström J., and Tilvis R. Two-hour glucose is a better predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose Eur Heart J 23 2002 1267 1275 (Pubitemid 35238508)
40. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., and Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose Diabetes Care 22 1999 920 924 (Pubitemid 29241045)
41. Succurro E., Marini M.A., Grembiale A., Lugara M., Andreozzi F., and Sciacqua A. Differences in cardiovascular risk profile based on relationship between post-load plasma glucose and fasting plasma levels Diabetes Metab Res Rev 25 2009 351 356
42. Nordestgaard B.G., Benn M., Schnohr P., and Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women JAMA 298 2007 299 308 (Pubitemid 47080484)
43. Freiberg J.J., Tybjaerg-Hansen A., Jensen J.S., and Nordestgaard B.G. Nonfasting triglycerides and risk of ischemic stroke in the general population JAMA 300 2008 2142 2152
44. Onat A., Hergenç G., Can G., Kaya Z., and Yüksel H. Complement C3: a determinant of cardiometabolic risk, additive to metabolic syndrome, in middle-aged population Metabolism 59 2010 628 634
45. Than T.S., Sattar N., Williams K., Gonzales-Villapando C., Lean M.E.J., and Haffner S.M. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study Diabetes Care 25 2002 2016 2021 (Pubitemid 41071061)
46. Laaksonen D.E., Niskanen L., Nyyssonen K., Punnonen K., Tuomainen T.P., and Valkonen V.P. C-reactive protein and the development of metabolic syndrome and diabetes in middle-aged men Diabetologia 47 2004 1403 1410
47. Timpson N.J., Lawlor D.A., Harbord R.M., Gaunt T.R., Day I.N.M., and Palmer L.J. C-reactive protein and its role in metabolic syndrome: mendelian randomization study Lancet 366 2005 1954 1959 (Pubitemid 41713985)
48. Onat A., Hergenç G., Keleş I., Doǧan Y., Türkmen S., and Sansoy V. Sex difference in development of diabetes and cardiovascular disease on the way from obesity and metabolic syndrome: prospective study of a cohort with normal glucose metabolism Metabolism 54 2005 800 808 (Pubitemid 40731508)
49. 2 group V of lipoproteins in diabetic dyslipidaemia J Internal Med 264 2008 155 165 (Pubitemid 351962571)
50. Fruchart J.C., Sacks F.M., Hermans M.P., Assmann G., Brown W.V., and Ceska R. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients Diabetes Vasc Dis Res 5 2008 319 335
51. de Rekeneire N., Peila R., Ding J., Colbert L.H., Visser M., and Shorr R.I. Diabetes, hyperglycemia, and inflammation in older individuals: the Health, Aging, and Body Composition study Diabetes Care 29 2006 1902 1908 (Pubitemid 44156650)
52. Onat A., Özhan H., Esen A.M., Albayrak S., Karabulut A., and Can G. Prospective epidemiologic evidence of a "protective" effect of smoking on metabolic syndrome and diabetes among Turkish women-without associated overall health benefit Atherosclerosis 193 2007 380 389
53. Rimm E.B., Manson J.E., Stampfer M.J., Colditz G.A., Willett W.C., and Rosner B. Cigarette smoking and the risk of diabetes in women Am J Publ Health 83 1993 211 214 (Pubitemid 23046478)
54. Onat A., Ayhan E., Hergenç G., Can G., and Barlan M.M. Smoking inhibits visceral fat accumulation in Turkish females: relation of visceral fat and body fat mass to atherogenic dyslipidemia, inflammatory markers, insulin resistance and blood pressure Metabolism 58 2009 963 970
55. Onat A., Hergenç G., Uǧur M., Can G., Ordu S., and Dursunoǧlu D. Lifestyle and metabolic determinants of incident hypertension, with special reference to cigarette smoking: a longitudinal population-based study Am J Hypertens 22 2009 156 162
56. Onat A., Hergenç G., Ayhan E., Kaya H., Tuncer M., and Can G. Serum apolipoprotein C-III in high-density lipoprotein: a key diabetogenic risk factor in Turks Diabet Med 26 2009 981 988
57. Waterworth D., Talmud P.J., Bujac S.R., Fisher R.M., Miller G.J., and Humphries S.E. Contribution of apolipoprotein C-III gene variants to determination of triglyceride levels and interaction with smoking in middle-aged men Arterioscler Thromb Vasc Biol 20 2000 2663 2669
58. Sykes A.P., Brampton C., Klee S., Chander C.L., Whelan C., and Parsons M.E. An investigation into the effect and mechanisms of action of nicotine in inflammatory bowel disease Inflamm Res 49 2000 311 319
59. Saeed R.W., Varma S., Peng-Nemeroff T., Sherry B., Balakhaneh D., and Huston J. Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation J Exp Med 201 2005 1113 1123 (Pubitemid 40524679)
60. Lindblad S.S., Mydel P., Jonsson I.M., Senior R.M., Tarkowski A., and Bokarewa A. Smoking and nicotine exposure delay development of collagen-induced arthritis in mice Arthritis Res Ther 11 2009 R88 10.1186/ar2728
61. Onat A., Hergenç G., Karabulut A., Albayrak S., Can G., and Kaya Z. Serum sex hormone-binding globulin, a determinant of cardiometabolic disorders independent of abdominal obesity and insulin resistance in elderly men and women Metabolism 56 2007 1356 1362 (Pubitemid 47407754)
62. Ding E.L., Song Y., Manson J.E., Hunter D.J., Lee C.C., and Rifai N. Sex hormone-binding globulin and risk of type 2 diabetes in women and men N Engl J Med 361 2009 [Epub]
63. Navab M., Hama S.Y., Ananthramaiah G.M., Hassan K., Hough G.P., and Rahmani S. Normal high-density lipoprotein inhibits three steps in the formation of mildly oxidized low-density lipoprotein: steps 2 and 3 J Lipid Res 41 2000 1495 1508
64. Kontush A., and Chapman M.J. Why is HDL functionally deficient in type 2 diabetes? Curr Diab Rep 8 2008 51 59 (Pubitemid 351384876)
65. Navab M., Ananthramaiah G.M., Reddy S.T., Van Lenten B.J., Ansell B.J., and Fonarow G.C. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL J Lipid Res 45 2004 993 1007 (Pubitemid 38679495)
66. Smith J.D. Dysfunctional HDL as a diagnostic and therapeutic target Arterioscler Thromb Vasc Biol 30 2010 151 155
67. Coleman R.L., Stevens R.J., Retnakaran R., and Holman R.R. Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes Diabetes Care 30 2007 1292 1294 (Pubitemid 46684668)
68. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP) JAMA 285 2001 2486 2497
69. Briel M., Ferreira-Gonzales I., You J.J., Karanicolas P.J., Akl E.A., and Wu P. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis BMJ 338 2009 b92 10.1136/bmj.b92
70. Ogasawara K., Mashiba S., Hashimoto H., Kojima S., Matsuno S., and Takeya M. Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apoAI-LDL) as a novel marker of coronary artery disease Clin Chim Acta 397 2008 42 47
71. Blankenhorn D.H., Alaupovic P., Wickham E., Chin H.P., and Azen S.P. Prediction of angiographic change in native human coronary arteries and coronary bypass grafts. Lipid and nonlipid factors Circulation 81 1990 470 476 (Pubitemid 20055954)
72. 2+-dependent β cell death in type 1 diabetes Proc Natl Acad Sci U S A 101 2004 10090 10094 (Pubitemid 38891199)
73. Asleh R., Blum S., Kalet-Litman S., Alshiek J., Miller-Lotan R., and Asaf R. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype Diabetes 57 2008 2794 2800
74. Henderson R.J., Wasan K.M., and Leon C.G. Haptoglobin inhibits phospholipid transfer protein activity in hyperlipidemic human plasma Lipids Health Dis 8 2009 27
75. Tohidi M., Hatami M., Hadaegh F., Safarkhani M., Harati H., and Azizi F. Lipid measures for prediction of incident cardiovascular disease in diabetic and non-diabetic adults: results of the 8.6-year follow-up of a population based cohort study Lipids Health Dis 9 2010 6 10.1186/1476-511X-9-6
76. Hu F.B., Stampfer M.J., Solomon C.G., Liu S., Willett W.C., and Speizer F.E. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up Arch Intern Med 161 2001 1717 1723 (Pubitemid 32679546)
77. Dale A.C., Nilsen T.I., Vatten L., Midthjell K., and Wiseth R. Diabetes mellitus and risk of fatal ischaemic heart disease by gender: 18 years follow-up of 74 914 individuals in the HUNT 1 Study Eur Heart J 28 2007 2924 2929 (Pubitemid 350233026)
78. Moerland M., Samyn H., van Gent T., Jauhiainen M., Metso J., and van Haperen R. Atherogenic, enlarged, and dysfunctional HDL in human PLTP/apoA-I double transgenic mice J Lipid Res 48 2007 2622 2631 (Pubitemid 350272847)
79. Cheung M.C., Brown B.G., Larsen E.K.M., Frutkin A.D., O'Brien K.D., and Albers J.J. Phospholipid transfer protein activity is associated with inflammatory markers in patients with cardiovascular disease Biochim Biophys Acta 1762 2006 131 137 (Pubitemid 43021095)
80. Kaser S., Sandhofer A., Föger B., Ebenbichler C.F., Igelseder B., and Malaimare L. Influence of obesity and insulin sensitivity on phospholipid transfer protein activity Diabetologia 44 2001 1111 1117 (Pubitemid 32835502)
81. Schlitt A., Bickel C., Thumma P., Blankenberg S., Rupprecht H.J., and Meyer J. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease Arterioscler Thromb Vasc Biol 23 2003 62
82. Schneider M., Vergés B., Klein A., Miller E.R., Deckert V., and Desrumaux C. Alterations in plasma vitamin E distribution in type 2 diabetic patients with elevated plasma phospholipid transfer protein activity Diabetes 53 2004 2633 2639 (Pubitemid 39299272)
83. Charles-Schoeman C., Watanabe J., Lee Y.Y., Furst D.E., Amjadi S., and Elashoff D. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis Arthritis Rheum 60 2009 2870 2879
84. Kömürcü-Bayrak E., Onat A., Poda M., Humphries S.E., Palmen J., and Güçlü F. Gender-modulated impact of apolipoprotein A5 gene (APOA5) -1131T>C and c.56C>G polymorphisms on lipids, atherogenic dyslipidemia and metabolic syndrome in Turkish adults Clin Chem Lab Med 46 2008 778 784 (Pubitemid 351821636)
85. Dodani S. Excess coronary artery disease risk in South Asian immigrants: can dysfunctional high-density lipoprotein explain increased risk? Vasc Health Risk Manag 4 2008 953 961
86. Zhang L., Qiao Q., Tuomilehto J., Janus E.D., Lam T.H., and Ramachandran A. Distinct ethnic differences in lipid profiles across glucose categories J Clin Endocrinol Metab 95 2010 1793 1801
87. Fox K.A.A., Després J.P., Richard A.J., Brette S., Deanfield J.E. on behalf of the IDEA Steering Committee and National Co-ordinators Does abdominal obesity have a similar impact on cardiovascular disease and diabetes? A study of 91,246 ambulant patients in 27 European countries Eur Heart J 30 2009 3055 3063
88. 10 triglyceride/ high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes and vascular events J Clin Lipidol 4 2010 89 98
89. The Diabetes Prevention Program Research Group Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance Diabetes 54 2005 1566 1572
90. Asztalos B.F., Horvath K.V., McNamara J.R., Roheim P.S., Rubinstein J.J., and Schaefer E.J. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients Atherosclerosis 164 2002 361 369 (Pubitemid 35223088)
91. Rosenson R.S. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities Atherosclerosis 173 2004 1 12 (Pubitemid 38228462)
92. Ridker P.M., Danielson E., Fonseca F.A.H., Genest G., Gotto A.M., and Kastelein J.J.P. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
93. Sattar N., Preiss D., Murray H., and Welsh P. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials Lancet 375 2010 735 742
94. Ky B., Burke A., Tsimikas S., Wolfe M.L., Tadesse M.G., and Szapary P.O. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic individuals J Am Coll Cardiol 51 2008 1653 1662 (Pubitemid 351626406)
95. Thiess F., Garry J.M., and Yaqoob P. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomized controlled trial Lancet 361 2003 477 485 (Pubitemid 36173713)
96. Ascherio A., Rimm E.B., Stampfer M.J., Giovannucci E.L., and Willett W.C. Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary disease among men N Engl J Med 332 1995 977 982
97. Ebbesson S.O.E., Roman M.J., Devereux R.B., Kaufman D., Fabsitz R.R., and MacCluer J.W. Consumption of omega-3 fatty acids is not associated with a reduction in carotid atherosclerosis: the Genetics of Coronary Artery Disease in Alaska Natives study Atherosclerosis 199 2008 346 353 (Pubitemid 352020410)